| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |